Key regions: Brazil, India, Australia, United States, United Kingdom
The demand for Antiviral Drugs in Malta has been on the rise in recent years.
Customer preferences: The increase in demand for Antiviral Drugs in Malta can be attributed to the growing awareness among the population about the importance of preventive healthcare. People are now more conscious about maintaining good health and are willing to invest in medications that can help them stay healthy. Additionally, the aging population in Malta has also contributed to the growing demand for Antiviral Drugs.
Trends in the market: One of the major trends in the Antiviral Drugs market in Malta is the shift towards generic drugs. Generic drugs are becoming increasingly popular among consumers due to their affordability and accessibility. This trend is expected to continue in the coming years as more generic drugs become available in the market.Another trend in the Antiviral Drugs market in Malta is the increasing use of combination therapies. Combination therapies involve the use of two or more drugs to treat a particular condition. These therapies have been found to be more effective than single drug therapies and are becoming more popular among healthcare providers in Malta.
Local special circumstances: One of the unique circumstances in Malta is that the country has a national healthcare system which provides free healthcare to all citizens. This has contributed to the high demand for Antiviral Drugs as people are more likely to seek medical attention when they need it. Additionally, the country has a small population which makes it easier to track and manage outbreaks of viral diseases.
Underlying macroeconomic factors: The Antiviral Drugs market in Malta is expected to continue growing in the coming years due to the country's aging population and the increasing prevalence of viral diseases. The government's focus on preventive healthcare is also expected to contribute to the growth of the market. However, the market may face challenges in the form of increasing competition from generic drugs and regulatory hurdles.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
